drugset / Trial / NCT06192615

Minimizing ICU Neurological Dysfunction With Dexmedetomidine-induced Sleep (MINDDS II)

NCT06192615

Phase 3 Recruiting 1800 enrolled Massachusetts General Hospital
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This is a pragmatic phase III, randomized, blinded, double placebo-controlled, three-arm trial of elderly patients following cardiac surgery to assess the relationship between nighttime intravenous (IV) and sublingual dexmedetomidine on postoperative delirium and functional outcomes after surgery.

Timeline

Start
2025-01-06
Primary completion
2027-10-31
Completion
2029-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified 1 ug/kg Intravenous
Subject Dexmedetomidine Other / unclassified 120 ug Intravenous

Indications